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Insufficient treatment adherence after early childhood 
is frequently observed in patients with phenylketonuria. 
Assessment of these individuals’ long-term metabolic 
control could enable early detection of the risk of intel-
lectual deterioration resulting from high blood pheny-
lalanine concentration. However, the predictive value 
of specific parameters related to individual dynamics of 
hyperphenylalaninemia is not clear. Here, we assessed 
the impact of blood phenylalanine fluctuations during 
the first 12 years of life on cognitive outcome in early 
and continuously treated teenagers with phenylketonu-
ria. We have analyzed a total of 5141 results of blood 
phenylalanine measurements in 32 patients. The pheny-
lalanine levels of these patients were usually acceptable 
during their early childhood, but the control of hyper-
phenylalaninemia worsened and the average treatment 
adherence dropped to 40% during the late primary 
school. Our analysis revealed a strong association be-
tween the Wechsler intelligence verbal scores and the 
mean of the yearly means of phenylalanine concentra-
tions (r=–0.62). The correlations of IQ scores with me-
dian phenylalanine concentrations and the variability 
of blood phenylalanine levels gave weaker associations. 
The Wechsler verbal scores were also strongly correlated 
with the treatment adherence level during preschool 
and late primary school (r=0.61 and 0.72). The mean of 
the yearly means of blood phenylalanine concentrations 
appears to be a better predictor of cognitive outcome 
in children with phenylketonuria than other parameters 
related to phenylalanine fluctuations. The percentage of 
acceptable phenylalanine levels below 50–60% should 
be regarded as a “red flag” due to the risk of intellectual 
deterioration in patients.
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INTRODUCTION
Phenylketonuria (PKU; OMIM 261600) is the most 
common inborn error of amino acid metabolism. A lack 
of sufficient treatment leads to progressive, irreversible 
brain damage (Burgard et al., 1997; Blau et al., 2010). De-
pending on the duration and extent of hyperphenylala-
ninemia, the signs and symptoms of insufficiently treated 
PKU can range from severe intellectual disability to sub-
tle neuropsychological abnormalities with decreased qual-
ity of life (Waisbren et al., 2007; Bik-Multanowski et al., 
2008).
Phenylketonuria treatment consisting of a life-long 
low-phenylalanine diet should be implemented before 
the end of the third week of life. According to current 
European treatment policies (van Spronsen et al., 2017), 
blood phenylalanine (Phe) concentration should be main-
tained within a range of 2–6 mg/dL (0.12–0.36 mmol/L; 
1 mg/dL=0.06 mmol/L) during the first 12 years of life 
and should not exceed 10 mg/dL in older patients.
It is generally accepted that a strict dietary regimen 
promotes normal intellectual development in PKU pa-
tients. Unfortunately, due to the pronounced burden of 
maintaining a low-phenylalanine diet, insufficient treat-
ment adherence is frequently observed among patients 
(Walter et al., 2002), and Phe concentrations often exceed 
the recommended range. Moreover, because the signs of 
phenylalanine toxicity develop slowly, intellectual deficits 
can remain subtle for a long time. Therefore, the risk 
of development of intellectual disability in young patients 
with PKU is considerable.
Follow-up procedures of PKU patients mainly include 
frequent blood Phe measurements and subsequent ad-
justment of dietary prescriptions to maintain the blood 
Phe concentration within the targeted ranges. The quality 
of long-term metabolic control can be used to predict 
the risk of intellectual deterioration in a given patient. 
However, it is not clear which of the parameters related 
to Phe concentration (e.g., the mean, the median or the 
changeability of Phe levels) should be watched to predict 
the cognitive deficits in PKU children (Viau et al., 2001; 
Anastasoaie et al., 2008; Blau et al., 2010).
In order to define the best Phe-related predictors of 
suboptimal intellectual outcome, we have analyzed the 
life-long Phe fluctuations in teenagers with PKU who 
were followed up in our clinic.
MATERIALS AND METHODS
A total of 32 teenagers (17 girls and 15 boys), aged 
12–15, with classic or mild PKU were included in the 
study. All of the patients had been followed up in our 
outpatient metabolic clinic since infancy. Dietary treat-
ment was introduced prior to the end of the third week 
of life. Table 1 lists the details of the study participants, 
including their treatment introduction time and the dis-
ease-causing mutations of the phenylalanine hydroxylase 
gene (PAH).
All of the results of blood Phe measurements, avail-
able since the neonatal period until the end of the 12th 
year of life, were assessed for the study participants. The 
Wechsler Intelligence Scale for Children (WISC-R) was 
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used to assess the intellectual status of every patient be-
tween the 13th and 15th year of life.
In order to identify the strongest predicting risk fac-
tors of intellectual disability, we have analyzed the corre-
lation of the Wechsler tests (full score, verbal score and 
performance score) with long-term dynamics of hyper-
phenylalaninemia. The Phe-related parameters included: 
the total number of blood Phe measurements, the mean 
of the 12 yearly mean concentrations during the first 
12 years of life, the median blood Phe concentrations 
within the same period and standard deviation (S.D.) of 
blood Phe concentrations, representing the variability of 
Phe concentrations, assessed separately for two periods: 
0–6 years and 6–12 years.
 Additionally, we analyzed the 
percentage of Phe measurements 
remaining within the recommend-
ed range (an indicator of treat-
ment adherence of the patients) 
for every patient. These analyses 
were conducted only for older 
children and young adolescents, 
separately for three developmen-
tal intervals: preschool (5th–6th 
years of life), early primary school 
(7th–9th years of life) and the late 
primary school (10th–12th years 
of life). We selected these periods 
based on the observed tendency 
of treatment adherence to de-
crease after early childhood (Wal-
ter et al., 2002).
Two-sided Pearson correlation 
statistics were used. We applied 
the Bonferroni correction for mul-
tiple comparisons to assess the 
statistical significance of the cor-
relation coefficient r.
RESULTS
A total of 5141 results of blood 
Phe measurements were analyzed. 
On average, 161 dry blood-spot 
tests were performed for each 
patient. The mean Phe concen-
tration during the first year of 
life (including the period of diet 
introduction and stabilization) ex-
ceeded 8 mg dL and subsequently 
decreased below 7 mg/dL to sta-
bilize for the next few years near 
6.5 mg/dL. It then rose to ap-
proximately 8 mg/dL during the 
10th–12th years of life. The S.D. 
of blood Phe concentrations with-
in the first six years of life were 
relatively high and reached 6.65 
mg/dL. However, it should be 
noted that the above period in-
cluded the initial period of diet in-
troduction and stabilization. In the 
following years (7th–12th years), 
the mean S.D. decreased to 3.73 
mg/dL.
The indicator of treatment ad-
herence (the percentage of accept-
able Phe results) slightly exceeded 
50% during preschool and early 
primary school (5th–9th years of life). This indicator 
then dropped to 40% during the late primary school pe-
riod.
The results of the WISC-R test varied between 91 and 
141 points with a median IQ within the normal/above-
average range (i.e., 114.5 points).
Data analysis of Phe fluctuations revealed a statistical-
ly significant association between Wechsler verbal scores 
and Phe values. In particular, a moderate correlation 
with the mean of the yearly Phe means was observed 
in the first 12 years of life (r=–0.62). The correlations 
of the median Phe concentrations in the same period, 
as well as of the S.D. of the Phe concentrations in older 
Table 1. The studied population.
Patient’s
number
Age at psycholo-
gical assessment Gender
Mutations 
of the PAH gene
Treatment start
(week of life)
I 13 M p.R408W/p.R408W 2
II 15 F p.R408W/IVS12+1g>a 3
III 12 F p.R408W/p.R243Q 3
IV 12 F p.R408W/p.L348V 3
V 12 M p.R408W/p.R158Q 2
VI 15 M p.R408W/p.R408W 3
VII 12 F p.R408W/p.R408W 2
VIII 14 F p.R408W/p.R408W 2
IX 12 F p.R408W/p.E183Q 2
X 14 F p.R408W/p.R408W 2
XI 15 M p.R408W/p.R408W 3
XII 12 M p.R408W/p.R408W 2
XIII 12 M p.R408W/p.R408W 3
XIV 13 M p.R252W/IVS10-11g>a 3
XV 15 M p.R408W/p.R408W 3
XVI 14 M p.R408W/p.R408W 3
XVII 15 M p.R408W/IVS2+5g>c 2
XVIII 14 F p.R408W/p.R408W 2
XIX 15 F p.R408W/p.R408W 3
XX 14 M p.R408W/IVS9-2a>c 3
XXI 12 F p.R408W/p.R408W 2
XXII 15 M p.R408W/p.R408W 3
XXIII 14 M p.R408W/p.R243Q 3
XXIV 15 F p.R408W/N 3
XXV 13 F p.R408W/p.R408W 2
XXVI 12 M p.R408W/IVS12+1g>a 3
XXVII 12 F p.R408W/p.R408W 2
XXVIII 13 F p.R408W/p.R408W 2
XXIX 14 F p.R408W/p.R408W 3
XXX 14 F p.R408W/N 3
XXXI 14 M p.R408W/p.R408W 3
XXXII 13 F p.R408W/p.R408W 2
N, not identified
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patients (7th–12th years), with verbal scores were weaker 
(r=–0.55 and –0.57, respectively).
The full Wechsler scores and the performance scores 
did not correlate significantly with any of the assessed 
parameters.
We next analyzed the correlations of IQ with treat-
ment adherence during the selected periods of life. The 
results attained statistical significance and revealed mod-
erate-to-strong correlations of verbal scores and treat-
ment adherence for all three analyzed periods: preschool, 
early primary school and the late primary school (r=0.61, 
0.54 and 0.72, respectively). Interestingly, correlation for 
the period corresponding to the 7th–9th years of life was 
the weakest and only minimally exceeded the threshold 
of statistical significance. The full Wechsler scores were 
significantly correlated with the treatment adherence only 
during the late primary school (r= 0.65), and the correla-
tions of the performance scores did not attain statistical 
significance.
The raw data of the blood Phe concentrations and the 
results of the psychological testing are presented in Ta-
ble 2. The results of statistical analyses can be found in 
Table 3. The relation between verbal scores and treat-
ment adherence in the late primary school period is pre-
sented in Fig. 1.
DISCUSSION
We have demonstrated that in the early and continu-
ously treated teenagers with PKU, the mean lifetime 
blood Phe levels are more closely related to cognitive 
outcome than the lifetime variability of blood Phe and 
the lifetime median Phe levels. We have also shown that 
the mean of the yearly mean Phe levels is the best bio-
chemical predictor of final IQ. This finding is somewhat 
at odds with previously published observations (Viau et 
al., 2001; Anastasoaie et al., 2008) that did not find any 
significant correlations between a high mean Phe and a 
poor cognitive outcome. However, the observed discrep-
ancies might be related to the population characteristics 
since the studies referenced above were largely focused 
on younger patients. In older children, the mean Phe 
concentration increases and its effect becomes more 
pronounced, as observed in our data.
Interestingly, the average IQ score in our patients ex-
ceeded the expected mean value in the general popula-
tion (100 points). This raises questions on potential test-
ing bias and potential overestimation of IQ in these pa-
tients. The learning effect (every participant of this study 
has been already assessed with the use of the same ver-
sion of the WISC-R test in the early primary school pe-
riod), or the so-called Flynn effect, referring to “ageing” 
of the test resulting in a rise of the average test scores in 
a population over time (Flynn et al., 1987), could partially 
explain this finding. However, it should be also noted, 
that the parents of children with well-controlled PKU 
make every effort to stimulate the cognitive development 
of their children, and some forms of cognitive training 
could result in an increase of the test scores obtained by 
this group of patients.
Our data confirmed that treatment adherence, which 
can be measured by means of the percentage of Phe 
levels within the recommended range, decreases from 
infancy through adolescence. Although the observed 
correlation of this parameter with IQ was the highest 
during late primary school, it was also significant dur-
ing preschool. These findings suggest that both periods 
are critical for the intellectual outcome of patients with 
PKU. Therefore, the development of more efficient fol-
low-up strategies specifically targeting preschool children 
and young teenagers should be considered to increase 
the safety of these patients and help them reach their 
full intellectual potential.
The second parameter, which could indirectly repre-
sent the treatment adherence (i.e., the frequency of Phe 
testing), did not correlate significantly with the IQ scores 
in our population. However, since the frequency of Phe 
testing depends on the stability of blood Phe and be-
cause some patients manage to maintain good metabolic 
control based on the results of only few tests adminis-
tered yearly, this parameter appears to be less informa-
tive for assessment of treatment adherence.
Although a worldwide consensus regarding optimal 
blood Phe levels in patients with PKU does not exist, 
current treatment policies in the majority of the devel-
oped countries (van Spronsen et al., 2017) focus on the 
necessity of maintaining Phe below 6 mg/dL in patients 
younger than 12 years of age. Our data support this rec-
ommendation. Careful data analysis leads to the conclu-
Table 3. Pearson’s correlation statistics. Bonferroni correction for multiple comparisons was applied. 
Corrected p-value is provided for statistically significant results (–0.51>r>0.51).
Total number 
of blood tests
Mean of 
yearly 
means
Median Phe 
values Phe S.D.
Treatment adherence (% of Phe re-
sults within the recommended range)
0–12 
years
0–12 
years
0–6 
years
7–12 
years
5–6 
years
7–9 
years
10–12 
years
Wechsler 
scale
scores
Full scale r=0.20 r=–0.47 r=–0.48 r=0.03 r=–0.42 r=0.51 r=0.44 r=0.65(p=0.001)
Verbal r=0.25 r=–0.62(p=0.004)
r=-0.55
(p=0.024) r=–0.07
r=–0.57
(p=0.015)
r=0.61
(p=0.005)
r=0.54
(p=0.031)
r=0.72
(p=0.0001)
Performance r=0.15 r=–0.30 r=-0.35 r=0.07 r=–0.28 r=0.34 r=0.31 r=0.50
Figure 1. Relation between the Wechsler verbal scores and 
treatment adherence during the late primary school period.
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sion that cognitive outcome is optimal in patients with 
a mean (the mean of the yearly means) Phe remaining 
below 6 mg/dL during the first 12 years of life. Howev-
er, since occasional spikes in blood Phe occur in nearly 
every child, a question arises: what is the maximal per-
centage of Phe levels exceeding the recommended range 
that is safe for patients? Although assessment of a larger 
number of patients with PKU appears to be necessary 
to ultimately answer this question, an analysis of Fig. 1 
suggests that a percentage below 50–60% decreases the 
likelihood of optimal intellectual development.
CONCLUSIONS
In summary, based on our observations, the mean of 
the yearly means of blood Phe concentration within the 
first 12 years of age appears to be a better predictor of 
cognitive outcome in children with PKU than other pa-
rameters related to hyperphenylalaninemia. Since the pre-
school (5th-6th year) and the late primary school periods 
seem to be critical for intellectual development, special 
care should be given to improving the metabolic stability 
of patients at this age. A percentage of acceptable Phe 
levels below 50–60% should be regarded as a “red flag” 
due to the risk of intellectual deterioration in patients.
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